Medexus Pharmaceuticals
Medexus Pharmaceuticals is a specialty pharmaceutical company based in Chicago that specializes in the development and commercialization of innovative treatments for rare and orphan diseases. The company focuses on several therapeutic areas, including hematology, rheumatology, oncology, auto-immune diseases, allergy, and pediatrics. With a strong commercial platform in North America, Medexus is dedicated to providing valuable solutions that address unmet medical needs in these critical areas, enhancing the quality of care for patients suffering from complex health conditions.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, Washington, dedicated to the discovery and development of innovative therapeutics for oncology and hematology. The company markets IXINITY, a coagulation factor IX treatment for hemophilia B, which is used for managing bleeding episodes. Its lead clinical candidate, APVO436, is currently undergoing Phase 1/1b trials for acute myeloid leukemia and high-grade myelodysplastic syndrome. Aptevo also has several preclinical candidates, including ALG.APV-527 and APVO603, which are designed using the ADAPTIR platform technology, aimed at enhancing immune responses against cancer. The company collaborates with Alligator Bioscience AB for the development of ALG.APV-527. Founded in 2016, Aptevo Therapeutics focuses on leveraging its proprietary technologies to improve patient outcomes in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.